Bid BH3 peptide acetate
Based on 1 Customer Validation
Bid BH3 peptide acetate is a pro-apoptotic peptide derived from the Bid protein. Through its α-helical conformation, Bid BH3 peptide inserts into the hydrophobic grooves of anti-apoptotic Bcl-2 family proteins (Bcl-xl, Bcl-2, Bcl-w and Bax), competitively displaces and releases the pro-apoptotic proteins Bax/Bak, thereby initiating mitochondrial outer membrane permeabilization (MOMP) and the caspase cascade for apoptosis. Bid BH3 peptide acetate can be used in cancer-related research.
For research use only. We do not sell to patients.
- Purity: 98.13%
- Formula: C74H127N29O24S·xC2H4O2
- Molecular Weight:1839.05 (free base)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Bid BH3 peptide acetate (10 μM; 6 h) acetate does not induce apoptosis in Jurkat E6.1 cells, while bivalent and pentavalent dextran-conjugated Bid BH3 peptide acetate increase caspase-3 activity by 12-fold and 21-fold, respectively, following nucleofection[1].
Monomeric Bid BH3 peptide (10 μM) acetate conjugated to nonaarginine does not induce apoptosis in Jurkat E6.1 cells, while bivalent and pentavalent dextran-conjugated Bid BH3 peptide acetate with nonaarginine increase caspase-3 activity by 7-fold and 17-fold, respectively[1].
Pentavalent dextran-conjugated Bid BH3 peptide (10 μM; 8 h) acetate induces early apoptosis in Jurkat E6.1 cells, as evidenced by Annexin-V staining and intact cell membrane integrity[1].
Bid BH3 peptide (0.05-0.07 mM) acetate is released as an unfolded species from its complex with truncated human BCL-w when BCL-w binds to 5-6 mM DPC micelles, and the released peptide binds to DPC micelles at concentrations up to 50 mM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Jurkat E6.1 lymphoma cells
-
Concentration:10 μM
-
Incubation Time:6 h
-
Result:Induced no significant apoptosis (no measurable increase in caspase-3 activity; monomeric form).
Increased caspase-3 activity by 12-fold (bivalent dextran-conjugated form).
Increased caspase-3 activity by 21-fold (pentavalent dextran-conjugated form).
-
Cell Line:Jurkat E6.1 lymphoma cells
-
Concentration:10 μM
-
Incubation Time:8 h
-
Result:Induced strong Annexin-V staining (indicative of early apoptosis) with intact cell membranes (trypan blue excluded from cells; pentavalent dextran-conjugated form).
Chemical Information
-
Appearance Solid
-
Molecular Weight 1839.05 (free base)
-
Formula C74H127N29O24S·xC2H4O2
-
Color White to off-white
-
SMILES
O=C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CNC=N1)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)C)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N.CC(O)=O.[x]
-
Sequence
Arg-Asn-Ile-Ala-Arg-His-Leu-Ala-Gln-Val-Gly-Asp-Ser-Met-Asp-Arg
-
Sequence Shortening
RNIARHLAQVGDSMDR
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References
[1]. Richter M, et al. Multivalent design of apoptosis-inducing bid-BH3 peptide-oligosaccharides boosts the intracellular activity at identical overall peptide concentrations. Chemistry (Weinheim an der Bergstrasse, Germany). 2012 Dec 21;18(52):16708-15. [Content Brief]
[2]. Denisov AY, et al. Structural model of the BCL-w-BID peptide complex and its interactions with phospholipid micelles. Biochemistry. 2006 Feb 21;45(7):2250-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bid BH3 peptide acetate Related Classifications
HY-P10614A Related Classifications
Powered by Bioz